Naltrexone
Psoriatic Arthritis
Brigham and Women's HospitalSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Psoriatic Arthritis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tirzepatide JULIO GRANADOS MONTIEL | Phase 4 | BBB |
Ixekizumab NHS Greater Glasgow and Clyde | Phase 3 | BB |
Nivolumab National Cancer Institute (NCI) | Phase 1 | CC |
Cabozantinib National Cancer Institute (NCI) | Phase 1 | CC |
Ipilimumab National Cancer Institute (NCI) | Phase 1 | CC |
Guselkumab University of California, San Diego | Unknown | D |
Metformin University of Alexandria | N/A | D |
Same molecule, other indications
Naltrexone is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →